Navigation Links
Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
Date:4/28/2010

BOCA RATON, Fla. April 28 /PRNewswire/ -- The X-GRAFT™ device is fashioned from solid human cortical bone, and is designed to acutely treat degenerative conditions of the spine. Utilizing the benefits of a minimal-exposure surgical procedure, the X-GRAFT™ is implanted into the interspinous space to provide stabilization of the spine, with minimal disturbance to the surrounding tissue. This is the first to market in a series of minimally invasive devices currently in development at Binder Biomedical and a key component of the MLIFF™ (Minimal - Lumbar, Interspinous, Facet Fusion) procedure.

Lawrence Binder, President of Binder Biomedical, Inc. commented: "The robust patent-pending design of the X-GRAFT™ device makes it an excellent option for stabilization of the lumbar spine following a decompression. The benefits of this system are evident from the favorable feedback we've received from our users. By offering a full range of sizes, as well as a comprehensive set of precision instruments, the X-GRAFT™ device has the unique ability to accommodate varying patient anatomy, while using minimal exposure, and fewer steps than traditional techniques."

The X-GRAFT™ device is procured and manufactured to exacting specifications by the University of Miami Tissue Bank (UMTB). This non-profit organization is the first civilian tissue bank in the U.S. and a university owned and operated tissue bank. UMTB is a comprehensive world-class facility, which conducts rigorous screening, recovery, autopsies, processing and packaging for all donors. Implantation of the 100th X-GRAFT™ is expected by the end of next month. Plans to expand national distributions are already underway, along with a full launch of the X-GRAFT™ device across the U.S. by the third quarter 2010. For more information on the X-GRAFT™ device please contact: sales@bindermed.com

Binder Biomedical, Inc. is a privately held medical device company located in Boca Raton, Florida. Founded on the basis of combining quality engineering with surgeon innovation, BBI provides surgeons with the highest quality medical devices for the treatment of complex orthopedic and neurological spinal disorders. Our development efforts are concentrated on products which incorporate advanced minimal exposure techniques, with the goal of providing better overall patient care. For more information about Binder Biomedical, Inc. please visit their website at:  www.bindermed.com


'/>"/>
SOURCE Binder Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
2. Competitive Technologies Selects RF
3. Binder as Public Relations Agency of Record
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):